J.P. Morgan analyst Robbie Marcus has maintained their bullish stance on EW stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Robbie Marcus has given his Buy rating due to a combination of factors tied to Edwards Lifesciences’ strong TRISCEND II outcomes and the strategic value of EVOQUE in tricuspid disease. The two-year data showed that patients treated with the EVOQUE transcatheter tricuspid valve replacement experienced meaningfully lower all-cause mortality versus optimal medical therapy, along with durable reductions in tricuspid regurgitation severity.
Robbie Marcus’s rating is based on the view that these clinical benefits, including sustained advantages in heart failure hospitalization trends and quality-of-life gains measured by KCCQ scores, reinforce EVOQUE’s differentiated profile. Despite complexities from early crossover in the control arm, Bayesian analyses continued to support a mortality benefit and superior patient-reported outcomes, which together strengthen the long-term commercial and growth outlook for Edwards Lifesciences.
According to TipRanks, Marcus is a 4-star analyst with an average return of 7.5% and a 51.30% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Boston Scientific, HeartFlow, Inc., and Integra Lifesciences.
In another report released yesterday, Citi also assigned a Buy rating to the stock with a $101.00 price target.